Improved Survival in Children with Graft Versus Host Disease Who Respond to Mesoblast's Cell Therapy

NEW YORK CITY and MELBOURNE, Australia, Feb. 15, 2015 -- Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for severe steroid-resistant acute Graft Versus Host Disease were presented at the 2015 American Society for Blood and Marrow Transplantation meeting in San Diego on 14 February. Lead investigator, Dr Joanne Kurtzberg, said the data from the initial 160 children enrolled in Mesoblast's Expanded Access Program Protocol 275 study continue to show a clear and meaningful survival benefit among responding pediatric bone marrow transplant recipients.

http://ift.tt/1vNLoXO